Write For Us

Hong Kong Stories - Inventors in Hong Kong：The Ingenious World of Neuroscience

E-Commerce Solutions SEO Solutions Marketing Solutions
26 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

ava
Published
Dementia remains an incurable condition, with current treatments only able to slow down its progression. Driven by dedication, medical scientist Owen Ko is determined to develop more effective therapies for delaying dementia caused by cerebral small vessel disease. Whether conducting scientific research or planning his own life journey, he chooses to traverse a winding and arduous path.

While most medical students aspire to become doctors, Owen took a different route. After completing two years of medical foundational courses at the Chinese University of Hong Kong (CUHK), he shifted his focus to neurophysiology research and spent four years in the United Kingdom to pursue a doctoral degree before returning to CUHK to complete the remaining medical courses, equipping himself as a medical scientist.

In 2016, Owen established his own laboratory. His research team analysed clinical data and conducted animal experiments, discovering that the use of GLP-1 receptor agonists, a type of diabetes medication, may slow down the progression of cerebral small vessel disease. They have now begun clinical trials, bringing hope for the development of future treatments to delay cerebral small vessel disease.

Although some may see Owen's laboratory as relatively new, his research has been published in prestigious scientific journals, and he has achieved recognition in the field of medicine. However, he often doubts his own intelligence and whether he can make significant contributions to human health.

With the mindset of a scientist and the compassion of a doctor, Owen continues to explore the intricate realm of neuroscience, while nurturing aspiring researchers to pursue the same goal.
Category
문화 - Culture
Tags
Cerebral small vessel disease, Dementia, GLP-1 receptor agonists
Sign in or sign up to post comments.
Be the first to comment